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Background / Objective
Prior use of “lymphocyte transformation test” (LTT) sug-
gested that it was less often positive in Stevens-Johnson
syndrome (SJS), Toxic Epidermal Necrolysis (TEN), than
in other cutaneous reactions, with possible dependence on
sampling date. We explored the possible role of inhibitory
co-receptors in LTT, using well-defined groups of patients
who reacted to carbamazepine (CBZ), or lamotrigine
(LTG), sulfamethoxazole (SMX) and allopurinol (ALL).
Method
Thirty one cases of SJS/TEN, and controls patients with
DRESS (21) or exposed without reaction (EWR; (20)) were
provided by the RegiSCAR group. Peripheral mononuclear
cells (PBMC) were tested by qRT-PCR for the expression
of the inhibitory co-receptors and their respective ligands:
PD-1/PDL1, CTLA4/B7.1. LTT was performed with
PBMCs by measuring H3-thymidine incorporation after 6
days incubation with CBZ/LTG/ALL (10µg/ml), SMX
(50µg/ml) or medium, in the presence or not of blocking
antibodies. Stimulation index ≥ 2.5 was considered positive.
Mann-Whitney U test was used for comparison of gene
expression level. A p value ≤0.05 was considered statistically
significant.
Results
Positive LTT was observed in 3/23 (13%) SJS/TEN and in
2/18 (11%) DRESS tested during the acute phase, and 7/22
(32%) SJS/TEN and 4/12 (33%) DRESS tested after recov-
ery (late). LTT were all negative in EWR. As compared to
their expression in PBMC of EWR, i) overexpression of
CTLA4 and of B7.1 was found in acute and late SJS/TEN,
respectively; ii) overexpression of PD-1 and PDL1 was
found in acute DRESS. Combined addition of anti-CTLA4
and anti-PDL1 mAbs to LTT cultures of SJS/TEN (2 CBZ
and 2 SMX) and DRESS (4 CBZ) increased drug-induced
proliferation index, even turning some negative LTT into
positive LTT (4 out of 8; 50%).
Conclusion
We confirm that reactive T cells are rarely detected in
acute phase of SCAR, and to a lesser extent after recov-
ery. We show for the first time that CTLA4- and PD-1
pathways are active in SJS/TEN and DRESS, respectively,
and may contribute to the negative reactivity of LTT.
The use of anti-CTLA4 and anti-PDL1 mAbs could help
to sensitize drug-specific LTT.
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